DEF: Harmony Biosciences Sets 2026 Annual Meeting Date

Harmony Biosciences Holdings, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 14, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Summary

• Harmony Biosciences Holdings, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 14, 2026, at 1:00 p.m. Eastern Time.
• The meeting will be conducted via live audio webcast at www.virtualshareholdermeeting.com/HRMY2026.
• Key agenda items include the election of four Class III directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote on the compensation of named executive officers (say-on-pay).
• The record date for determining stockholders entitled to vote is March 17, 2026, with 57,867,389 shares of common stock outstanding as of that date.
• Proxy materials are being furnished primarily via the Internet, with a Notice of Internet Availability expected to be mailed around April 3, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily due to its procedural nature as a proxy statement. While it outlines standard corporate governance and compensation practices, it also highlights positive pipeline progress and strong revenue growth for WAKIX in the prior year.

Positives

• The company is utilizing a virtual meeting format to enhance accessibility, communication, and cost savings for stockholders.
• The virtual format allows for broader participation from stockholders globally.
• The company is advancing its pipeline with progress in pediatric WAKIX approval and new formulations, alongside acquisitions and preclinical development.
• Harmony Biosciences reported strong net revenue growth for WAKIX in 2025, reaching $868.5 million, a 22% year-over-year increase.
• The company maintains a strong financial position with $882.5 million in cash, cash equivalents, and investments as of December 31, 2025.

Negatives

• The filing does not contain specific financial results for the fiscal year ended December 31, 2025, as it is a proxy statement for a future meeting.
• One of the key performance goals for the 2025 annual bonus program, 'Clinical Development Programs', was rated as 'Objective Not Completed'.

Risks

• The filing mentions that the board of directors oversees the company's risk management process, covering strategic, financial, business, operational, competitive, legal, compliance, cybersecurity, privacy, platform, product innovation, and reputational risks.
• The audit committee reviews major financial risk exposures, internal controls, disclosure controls, and cybersecurity and IT risks.
• The compensation committee reviews risks associated with executive compensation programs.
• The nominating and corporate governance committee reviews risks related to board membership, structure, and effectiveness.

Future Outlook

The filing does not provide specific forward-looking financial guidance but details the company's ongoing pipeline development, including planned NDA submissions for new formulations of pitolisant and initiation of Phase 3 trials. The company also acquired global rights to EPX-100 and began first-in-human studies for a preclinical orexin 2 receptor agonist.

Management Comments

• We believe that a virtual meeting provides expanded access, improved communication and cost savings for our stockholders and Harmony.
• We believe this is the right choice for a company with a global reach and worldwide stockholder base.
• We remain very conscious to any concerns that virtual meetings may diminish stockholder voice or reduce accountability.
• We believe that our long-term success depends largely on the talents of our employees. Our compensation program plays a significant role in our ability to attract, retain, and motivate the highest quality employees.
• We believe that our current compensation program directly links executive compensation to performance and the achievement of strategic goals, and aligns the interests of our executive officers with those of our stockholders.

Industry Context

StockSavvy.ai notes that Harmony Biosciences is operating in the competitive biopharmaceutical sector, with a focus on rare neurological diseases. The company's strategy involves advancing its WAKIX franchise, expanding its pipeline through internal development and acquisitions, and maintaining a strong financial position to support these efforts. The virtual annual meeting format aligns with broader trends in corporate governance and investor engagement.

Comparison to Industry Standards

• The company's executive compensation structure, including base salary, short-term incentives, and long-term equity awards, is benchmarked against a peer group of biopharmaceutical companies including Acadia, Axsome, Ionis, Neurocrine Biosciences, Supernus, Alkermes, Catalyst Pharma, Jazz Pharmaceuticals, PTC, Avadel, Intra-Cellular, Marinus, and Sage Therapeutics.
• The director compensation program includes annual retainers and equity grants, with cash compensation for committee chairs and members, and an annual retainer for the Non-Executive Chairman, which are standard practices in the industry.
• The company's approach to risk management, with oversight from the board and its committees, aligns with best practices for publicly traded companies, particularly in the highly regulated pharmaceutical industry.

Management Changes

Corporate Governance

Related Party Transactions

• A right of use agreement with Paragon Biosciences allows Harmony to use office space leased by Paragon, incurring $0.5 million in fees for 2025.
• A license agreement with CiRC Biosciences, Inc. (controlled by Paragon) resulted in $15.0 million in payments during 2025.

Stakeholder Impact

• Shareholders: Will vote on director elections, auditor ratification, and executive compensation. The virtual meeting format aims to increase participation.
• Management and Employees: Executive compensation is tied to performance, with equity awards and bonuses designed to retain talent and align interests. Stock ownership guidelines are in place.
• Auditors: Deloitte & Touche LLP is proposed for reappointment, with fees disclosed.
• Board of Directors: Nominees are presented for election, with qualifications detailed. Committee compositions are subject to change.

Next Steps

• Stockholders to elect four Class III directors.
• Stockholders to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
• Stockholders to vote on a non-binding, advisory basis on the compensation of named executive officers.
• The company will file a Current Report on Form 8-K with preliminary voting results within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a proxy statement for an upcoming annual meeting and does not contain new financial results or significant strategic updates that would warrant a change in investment recommendation. The information provided pertains to procedural matters, director elections, and compensation, which are standard for this type of filing. Investors should refer to separate financial reports for performance-based investment decisions.

Keywords

Harmony Biosciences, Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Executive Compensation, Say-on-Pay, WAKIX, Stockholder Vote, Corporate Governance